Our projects are centered on a functional understanding of molecular processes that drive initiation and progression of cancer. We employ genomics and proteomics to capture the cellular networks that modulate these processes and we seek to validate any new finding in vitro and in vivo in various models. A particular focus of our work is to combine computational biology as well as cell biology approaches with the goal of discovering new targets for cancer (immuno-) therapy.
We are looking for talented scientists driven by the desire to make a relevant contribution to the treatment of cancer patients through exciting scientific discoveries in the lab. The ability to work independently is a must. Successful candidates will have a strong background in basic molecular and cell biology, immunology, biochemistry, computational biology or similar areas.
Please submit your application including a detailed CV, list of publications, two references and a brief statement of research interests.
We offer a great work environment, intensive mentoring and several interactions with global leaders, both from academia and industry. In addition, the highly collaborative research environment in Cologne provides us with access to state-of-the-art core facilities, including genomics, proteomics and imaging.
Working at the University Hospital Cologne and the Medical Faculty means helping to shape the future - the future of medicine, of patients and, of course, your own future. You benefit from 59 clinics and institutes as well as numerous other departments and facilities and more than 10,000 jobs. The Faculty of Medicine of the University of Cologne and the University Hospital Cologne assume important social tasks in research, teaching and patient care. A close network with many university and non-university partners guarantees an internationally successful science and the excellent education of our students.
The Research Mission of the Department of Translational Genomics is to understand the impact of somatic genetic alterations in cancer cells on the highly complex regulatory network of signaling pathways. Therefor we link basic research and the application of new findings with translational research to close the loop, linking disciplines and delivering therapies to patients more rapidly.
Our Department is highly interdisciplinary, covering expertise in biochemistry and signaling, structural biology, medicinal chemistry and structure-guided drug design, cancer immunology and inflammation, molecular pathology, mouse models, cancer genomics as well as computational genomics.
We build our Department on a portfolio of established technological platforms, covering approaches involving genomics, immunomics, cellular models, genetically engineered mouse models (GEMMs) and imaging, as well as computational efforts to understand the molecular evolution of cancer. Particular emphasis is placed on carefully interrogating the discoveries made in large scale high-throughput assays in subsequent fine-grained mechanistic experiments. Our scientific efforts are intimately linked to the clinic through a translational platform, which facilitates the longitudinal molecular monitoring of patients, thus providing mechanisms of evolution and adaptation to therapy.